These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 34572886)
21. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients. Zhou F; Huang Y; Cai W; Li J; Su C; Ren S; Wu C; Zhou C Lung Cancer; 2021 Mar; 153():66-72. PubMed ID: 33454519 [TBL] [Abstract][Full Text] [Related]
22. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
23. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421 [TBL] [Abstract][Full Text] [Related]
24. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503 [TBL] [Abstract][Full Text] [Related]
25. A comprehensive pan-cancer analysis of Gao G; Zhang XD; Qu H; Yao B; Zhou Y; Xiang J; Chen C; Hou T; Chen K; Xu J Ann Transl Med; 2021 Apr; 9(8):677. PubMed ID: 33987375 [TBL] [Abstract][Full Text] [Related]
26. Highly sensitive duplex MSI test and BAT40 germline polymorphism. Kang SY; Kim KM APMIS; 2021 Oct; 129(10):607-615. PubMed ID: 34342050 [TBL] [Abstract][Full Text] [Related]
27. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability Jin Z; Yoon HH J Gastrointest Oncol; 2016 Oct; 7(5):771-788. PubMed ID: 27747091 [TBL] [Abstract][Full Text] [Related]
28. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma. He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103 [TBL] [Abstract][Full Text] [Related]
29. Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers. Contos G; Baca Y; Xiu J; Brown J; Holloway R; Korn WM; Herzog TJ; Jones N; Winer I Gynecol Oncol; 2021 Nov; 163(2):312-319. PubMed ID: 34563366 [TBL] [Abstract][Full Text] [Related]
30. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155 [TBL] [Abstract][Full Text] [Related]
31. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer. Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR Front Oncol; 2023; 13():1235902. PubMed ID: 37637072 [TBL] [Abstract][Full Text] [Related]
32. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779 [TBL] [Abstract][Full Text] [Related]
33. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06). Kim JW; Lee HJ; Lee JY; Park SR; Kim YJ; Hwang IG; Kyun Bae W; Byun JH; Kim JS; Kang EJ; Lee J; Shin SJ; Chang WJ; Kim EO; Sa JK; Park KH J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485184 [TBL] [Abstract][Full Text] [Related]
34. [Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer]. Wang XY; Hu YJ; Dong K; Zhao C; Huang XZ; Lian SY; Sun Y Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1114-1119. PubMed ID: 33152814 [No Abstract] [Full Text] [Related]
35. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847 [TBL] [Abstract][Full Text] [Related]
38. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Rizzo A; Ricci AD; Brandi G Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621 [TBL] [Abstract][Full Text] [Related]
39. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786 [TBL] [Abstract][Full Text] [Related]
40. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]